The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
What does the FIGARO trial reveal about predictors of outcome post-transplant?
Featured:
Charles CraddockDuring the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings), the MDS Hub was pleased to speak with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, What does the FIGARO trial reveal about predictors of outcome post-transplant?
What does the FIGARO trial reveal about predictors of outcome post-transplant?
Craddock begins by outlining the trial aims and design, which investigated the use of the FLAMSA-Bu conditioning regimen in adult patients with AML. Craddock outlines the study results, noting that the presence of pretransplant measurable residual disease (MRD) is still associated with increased risk of relapse, and the most important predictor of outcome. Finally, Craddock discusses full donor T-cell chimerism, and reduced intensity conditioning (RIC) allograft strategies and mechanisms.